Search research articles
Contact Us
Filters
Showing results (41-50 of 68) with videos related to
Page
of 7
Sort By:
Chromosome Research : an International Journal on the Molecular, Supramolecular and Evolutionary Aspects of Chromosome Biology
|
November 7, 2008
Physical map of two tammar wallaby chromosomes: a strategy for mapping in non-model mammals
Janine E Deakin, Edda Koina, Paul D Waters, et al.
Iscience
|
July 18, 2024
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and <i>CCNE1</i> amplified ovarian cancer
Haineng Xu, Sarah B Gitto, Gwo-Yaw Ho, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
January 6, 2026
High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
Andrew Farrell, Genevieve Dall, Cassandra J Vandenberg, et al.
International Journal of Cancer
|
April 12, 2020
ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer
Moonsun Jung, Jixuan Gao, Leanna Cheung, et al.
Plos Biology
|
January 27, 2006
Reconstructing an ancestral mammalian immune supercomplex from a marsupial major histocompatibility complex
Katherine Belov, Janine E Deakin, Anthony T Papenfuss, et al.
Molecular Oncology
|
February 25, 2014
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
Monique D Topp, Lynne Hartley, Michele Cook, et al.
Therapeutic Advances in Medical Oncology
|
November 29, 2023
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models
Gwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim, et al.
JCO Precision Oncology
|
February 1, 2022
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study
Olga Kondrashova, Gwo-Yaw Ho, George Au-Yeung, et al.
Nature Communications
|
May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
Elaine Sanij, Katherine M Hannan, Jiachen Xuan, et al.
Genome Biology
|
January 22, 2025
MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assays
Alan F Rubin, Jeremy Stone, Aisha Haley Bianchi, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 68) with videos related to
Sort By:
Page
of 7
Chromosome Research : an International Journal on the Molecular, Supramolecular and Evolutionary Aspects of Chromosome Biology
|
November 7, 2008
Physical map of two tammar wallaby chromosomes: a strategy for mapping in non-model mammals
Janine E Deakin, Edda Koina, Paul D Waters, et al.
Iscience
|
July 18, 2024
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and <i>CCNE1</i> amplified ovarian cancer
Haineng Xu, Sarah B Gitto, Gwo-Yaw Ho, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
January 6, 2026
High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
Andrew Farrell, Genevieve Dall, Cassandra J Vandenberg, et al.
International Journal of Cancer
|
April 12, 2020
ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer
Moonsun Jung, Jixuan Gao, Leanna Cheung, et al.
Plos Biology
|
January 27, 2006
Reconstructing an ancestral mammalian immune supercomplex from a marsupial major histocompatibility complex
Katherine Belov, Janine E Deakin, Anthony T Papenfuss, et al.
Molecular Oncology
|
February 25, 2014
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
Monique D Topp, Lynne Hartley, Michele Cook, et al.
Therapeutic Advances in Medical Oncology
|
November 29, 2023
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models
Gwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim, et al.
JCO Precision Oncology
|
February 1, 2022
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study
Olga Kondrashova, Gwo-Yaw Ho, George Au-Yeung, et al.
Nature Communications
|
May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
Elaine Sanij, Katherine M Hannan, Jiachen Xuan, et al.
Genome Biology
|
January 22, 2025
MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assays
Alan F Rubin, Jeremy Stone, Aisha Haley Bianchi, et al.
Page
of 7